Genprex to Present Positive Clinical Data on Biomarkers at 2026 ASCO Annual Meeting

Genprex Unveils Promising Clinical Evidence at ASCO 2026

Genprex, Inc., recognized as a leader in clinical-stage gene therapy, has made headlines with its forthcoming presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 29 to June 2, 2026. This prestigious event will be held in Chicago, where the company will disclose significant clinical data regarding predictive biomarkers related to their innovative treatment for lung cancer, Reqorsa® Gene Therapy (quaratusugene ozeplasmid).

The abstract titled "Predictive biomarkers for PFS in patients receiving quaratusugene ozeplasmid" has been selected for publication, demonstrating Genprex's commitment to advancing cancer care through groundbreaking research. As articulated by Genprex's President and CEO, Ryan Confer, the company is thrilled to share recent findings that may enhance the effectiveness of clinical trials for lung cancer patients. The identification of predictive biomarkers holds potential to forecast patient responses to Reqorsa, thereby improving treatment outcomes and survival rates.

Understanding Reqorsa® Gene Therapy

Reqorsa® Gene Therapy, distinguished for its multifaceted approach, targets tumor glucose metabolism, disrupts cellular signaling pathways linked to cancer cell replication, eliminates cancer cells, and boosts immune responses. The therapy works by re-expressing the TUSC2 protein while enhancing the population of anti-tumor immune cells, potentially increasing patient response to cancer treatment.

This gene therapy consists of a plasmid encapsulated in non-viral lipid nanoparticles, ensuring a high level of precision in delivering therapeutic genes directly to cancer cells with minimal impact on healthy cells. Administered intravenously, Reqorsa takes advantage of the distinct metabolic and molecular characteristics of cancer cells, leading to more effective treatment methodologies.

Laboratory studies at renowned institutions, including MD Anderson Cancer Center, indicate remarkable uptake of TUSC2 protein in tumor cells following Reqorsa treatment—showing 10 to 33 times more than in normal cells. Preliminary biopsies from patients reveal significant increases in TUSC2 protein expression, demonstrating the therapy's capability to modify the tumor microenvironment favorably.

Genprex's Vision and Future Goals

Genprex’s mission extends beyond lung cancer therapies. The company focuses on developing groundbreaking treatments for patients with various illnesses, including diabetes. Their ongoing projects include a novel gene therapy utilizing an AAV vector aimed at rejuvenating functional insulin-producing cells in Type 1 and Type 2 diabetes. By recruiting advanced technologies and collaborating with top-tier research institutions, Genprex aims to improve therapeutic strategies and outcomes for patients facing chronic diseases typically regarded as challenging to treat.

The 2026 ASCO Annual Meeting is expected to be a platform for Genprex to further their vision and showcase their achievements in the realm of gene therapy. For interested investors and health advocates, the upcoming presentation marks a critical point in the ongoing battle against cancer and chronic diseases—a testament to innovation, hope, and the relentless pursuit of medical breakthroughs.

By staying engaged with Genprex through their official channels, stakeholders can keep up-to-date with the latest developments in their pioneering research and therapeutic offerings. The excitement surrounding Reqorsa and the promising clinical data presented at ASCO 2026 is set to make a significant impact in the medical community, potentially steering the direction of future cancer treatments.